The content on this site is intended for healthcare professionals only
Dr Paul Richardson speaks to ecancer about the ICARIA-MM final overall survival analysis. Isatuximab-irfc plus pomalidomide and low-dose dexamethasone (Isa-Pd) continues to show clinically meaningful benefit for patients with relapsed or refractory multiple myeloma demonstrating an improved overall survival (OS) over pomalidomide alone.
At a median follow-up of 35.3 months, the median OS was 24.6 months in the isatuximab group vs 17.7 months in the Pd group. Overall, there were 220 OS events with 106 in the Isa-Pd arm and 114 in the Pd arm.
Dr Richardson explains that the final analysis of this study also examined the impact of the Isa-PD treatment in the real world by observing deaths due to COVID-19.
These findings were presented at the 19th International Myeloma Society annual meeting, where researchers found that COVID-19 negatively impacted the overall survival of the Isa-Pd arm.
He concludes by talking about the clinical value of these results.
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
